| scholarly article | Q13442814 |
| P50 | author | Marcus Altfeld | Q72531060 |
| Galit Alter | Q88683228 | ||
| Leonidas Stamatatos | Q89197121 | ||
| Noah Sather | Q92365148 | ||
| Spyros A Kalams | Q95979306 | ||
| P2093 | author name string | Iliyana Mikell | |
| P2860 | cites work | Cross‐Reactive Neutralizing Humoral Immunity Does Not Protect from HIV Type 1 Disease Progression | Q56886558 |
| Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load | Q58034113 | ||
| Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120 | Q72067428 | ||
| Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies | Q73732889 | ||
| Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies | Q24561905 | ||
| Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages | Q24642180 | ||
| Structural Basis of Immune Evasion at the Site of CD4 Attachment on HIV-1 gp120 | Q27658449 | ||
| T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1/Th2 effector cells that provide help for B cells | Q28268047 | ||
| Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target | Q29547347 | ||
| Rapid evolution of the neutralizing antibody response to HIV type 1 infection | Q29618603 | ||
| Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies | Q29619015 | ||
| Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 | Q29619512 | ||
| Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics. | Q30843874 | ||
| Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. | Q31016954 | ||
| An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10 | Q33272711 | ||
| Efficient recovery of high-affinity antibodies from a single-chain Fab yeast display library | Q33431668 | ||
| Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals | Q33526340 | ||
| Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables | Q33614495 | ||
| Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity | Q33826951 | ||
| PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells | Q33866996 | ||
| Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects | Q33888559 | ||
| A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals | Q34047445 | ||
| A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope | Q34078521 | ||
| Human anti-HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness | Q34096475 | ||
| Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. | Q34178201 | ||
| The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. | Q34341843 | ||
| The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. | Q34342352 | ||
| Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles | Q34406977 | ||
| Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1 | Q34648079 | ||
| Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses | Q34651668 | ||
| Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia | Q34848486 | ||
| In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth | Q34937404 | ||
| Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals | Q34962766 | ||
| Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterolo | Q35024202 | ||
| Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity | Q35101464 | ||
| Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa | Q35140032 | ||
| Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection | Q35635163 | ||
| Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors | Q35857221 | ||
| Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection | Q35857268 | ||
| Isolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens | Q36103090 | ||
| The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection | Q36483346 | ||
| Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1 | Q36625449 | ||
| Human antibody responses to HIV type 1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding | Q36818811 | ||
| Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. | Q36974754 | ||
| Broad HIV-1 neutralization mediated by CD4-binding site antibodies | Q36977635 | ||
| Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies | Q37033269 | ||
| Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection | Q37033294 | ||
| Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals | Q37033400 | ||
| Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm | Q37247974 | ||
| Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression | Q37356036 | ||
| Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region | Q37410792 | ||
| Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? | Q37519312 | ||
| Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4 | Q39610645 | ||
| Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site | Q39699375 | ||
| Assessment of antibody responses against gp41 in HIV-1-infected patients using soluble gp41 fusion proteins and peptides derived from M group consensus envelope | Q40145762 | ||
| Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. | Q40721814 | ||
| Independent evolution of human immunodeficiency virus type 1 env V1/V2 and V4/V5 hypervariable regions during chronic infection | Q42737939 | ||
| Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1. | Q42959357 | ||
| HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus | Q45732337 | ||
| Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression. | Q45948731 | ||
| HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry | Q46170039 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | e1001251 | |
| P577 | publication date | 2011-01-13 | |
| P1433 | published in | PLOS Pathogens | Q283209 |
| P1476 | title | Characteristics of the earliest cross-neutralizing antibody response to HIV-1. | |
| P478 | volume | 7 |
| Q28730532 | 9G4 autoreactivity is increased in HIV-infected patients and correlates with HIV broadly neutralizing serum activity |
| Q35081119 | 9G4+ antibodies isolated from HIV-infected patients neutralize HIV-1 and have distinct autoreactivity profiles |
| Q26829865 | A Blueprint for HIV Vaccine Discovery |
| Q57491418 | A Comprehensive Analysis of the T and B Lymphocytes Repertoire Shaped by HIV Vaccines |
| Q90434609 | A Coreceptor-Mimetic Peptide Enhances the Potency of V3-Glycan Antibodies |
| Q45008312 | AIDS/HIV. Converging on an HIV vaccine |
| Q33808304 | Abnormal B cell memory subsets dominate HIV-specific responses in infected individuals |
| Q52609661 | Advances in HIV-1 Vaccine Development |
| Q26824545 | Advances in structure-based vaccine design |
| Q34784825 | An HIV-1 envelope immunogen with W427S mutation in CD4 binding site induced more T follicular helper memory cells and reduced non-specific antibody responses. |
| Q92538491 | An Inflammatory Story: Antibodies in Tuberculosis Comorbidities |
| Q37680009 | An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. |
| Q35109028 | An investigation of the breadth of neutralizing antibody response in cats naturally infected with feline immunodeficiency virus |
| Q35382871 | Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors |
| Q64061234 | Ancestral sequences from an elite neutralizer proximal to the development of neutralization resistance as a potential source of HIV vaccine immunogens |
| Q35641369 | Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency |
| Q27011574 | Antibodies in HIV-1 vaccine development and therapy |
| Q84313050 | Antibodies that cross-neutralize the tier-2 pseudoviruses are produced in antiretroviral-naïve HIV-1-infected children from northern India |
| Q33786443 | Antibody 10-1074 suppresses viremia in HIV-1-infected individuals |
| Q35660279 | Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralization |
| Q35105449 | Antibody to the gp120 V1/V2 loops and CD4+ and CD8+ T cell responses in protection from SIVmac251 vaginal acquisition and persistent viremia |
| Q36363231 | Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family |
| Q34022578 | Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination |
| Q34008741 | B Cell Depletion in HIV-1 Subtype A Infected Ugandan Adults: Relationship to CD4 T Cell Count, Viral Load and Humoral Immune Responses |
| Q64973575 | B cell clonal lineage alterations upon recombinant HIV-1 envelope immunization of rhesus macaques. |
| Q59354834 | Bacterially expressed HIV-1 gp120 outer-domain fragment immunogens with improved stability and affinity for CD4-binding site neutralizing antibodies |
| Q35077716 | Binding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific monoclonal antibodies PG9 and PG16. |
| Q92280921 | Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope |
| Q33594304 | Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals |
| Q36131738 | Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein |
| Q36397394 | Broadly Neutralizing Antibodies Developed by an HIV-Positive Elite Neutralizer Exact a Replication Fitness Cost on the Contemporaneous Virus |
| Q91812746 | Broadly Neutralizing Antibodies against HIV: Back to Blood |
| Q33592852 | Broadly Neutralizing Antibodies as Treatment: Effects on Virus and Immune System |
| Q35894094 | Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort |
| Q46683819 | Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning |
| Q56974226 | Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy? |
| Q100430434 | Characteristics of HIV-1 env genes from Chinese chronically infected donors with highly broad cross-neutralizing activity |
| Q40581381 | Chronic HIV-1 Infection Impairs Superantigen-Induced Activation of Peripheral CD4+CXCR5+PD-1+ Cells, With Relative Preservation of Recall Antigen-Specific Responses |
| Q35861256 | Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research |
| Q51427423 | Complex binding sites made to order |
| Q92727230 | Conjugation of an scFab domain to the oligomeric HIV envelope protein for use in immune targeting |
| Q36434294 | Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites |
| Q36105782 | Cross-reactive broadly neutralizing antibodies: timing is everything |
| Q30397595 | Current views on the potential for development of a HIV vaccine |
| Q36742228 | Design of an Escherichia coli expressed HIV-1 gp120 fragment immunogen that binds to b12 and induces broad and potent neutralizing antibodies |
| Q57182355 | Design, display and immunogenicity of HIV1 gp120 fragment immunogens on virus-like particles |
| Q37069837 | Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection. |
| Q40476608 | Determinants of HIV-1 broadly neutralizing antibody induction. |
| Q41933100 | Development and optimization of a sensitive pseudovirus-based assay for HIV-1 neutralizing antibodies detection using A3R5 cells |
| Q36736392 | Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques |
| Q40047250 | Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies |
| Q27022652 | Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection |
| Q37042563 | Development of prophylactic vaccines against HIV-1. |
| Q37551245 | Differences in Allelic Frequency and CDRH3 Region Limit the Engagement of HIV Env Immunogens by Putative VRC01 Neutralizing Antibody Precursors |
| Q35092308 | Directed evolution of a yeast-displayed HIV-1 SOSIP gp140 spike protein toward improved expression and affinity for conformational antibodies |
| Q89673923 | Discovery of O-Linked Carbohydrate on HIV-1 Envelope and Its Role in Shielding against One Category of Broadly Neutralizing Antibodies |
| Q37644030 | Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D. |
| Q36194234 | Diversification in the HIV-1 Envelope Hyper-variable Domains V2, V4, and V5 and Higher Probability of Transmitted/Founder Envelope Glycosylation Favor the Development of Heterologous Neutralization Breadth |
| Q34594036 | Drift of the HIV-1 envelope glycoprotein gp120 toward increased neutralization resistance over the course of the epidemic: a comprehensive study using the most potent and broadly neutralizing monoclonal antibodies. |
| Q59356085 | Durable targeting of B-lymphocytes in living mice |
| Q33764917 | Early development of broadly neutralizing antibodies in HIV-1-infected infants |
| Q34594726 | Early preservation of CXCR5+ PD-1+ helper T cells and B cell activation predict the breadth of neutralizing antibody responses in chronic HIV-1 infection |
| Q34594701 | Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1 |
| Q37036833 | Emergence of gp120 V3 Variants Confers Neutralization Resistance in an R5 Simian-Human Immunodeficiency Virus-Infected Macaque Elite Neutralizer That Targets the N332 Glycan of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein |
| Q34687653 | Emerging concepts on T follicular helper cell dynamics in HIV infection |
| Q36750045 | Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies |
| Q36956100 | Engineering Recombinant Reoviruses To Display gp41 Membrane-Proximal External-Region Epitopes from HIV-1 |
| Q34594513 | Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits. |
| Q37426168 | Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses |
| Q34819651 | Evidence for a Continuous Drift of the HIV-1 Species towards Higher Resistance to Neutralizing Antibodies over the Course of the Epidemic |
| Q37254327 | Evolution of broadly cross-reactive HIV-1-neutralizing activity: therapy-associated decline, positive association with detectable viremia, and partial restoration of B-cell subpopulations |
| Q34478071 | Evolution of cross-neutralizing antibody specificities to the CD4-BS and the carbohydrate cloak of the HIV Env in an HIV-1-infected subject |
| Q36707546 | Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions |
| Q35540085 | Functional and Molecular Characteristics of Novel and Conserved Cross-Clade HIV Envelope Specific Human Monoclonal Antibodies |
| Q35168642 | Functional characterization of two scFv-Fc antibodies from an HIV controller selected on soluble HIV-1 Env complexes: a neutralizing V3- and a trimer-specific gp41 antibody. |
| Q38992744 | Genetic and structural analyses of affinity maturation in the humoral response to HIV-1. |
| Q51034749 | Genetic evolution in immunization |
| Q34571277 | Genome-wide association study on the development of cross-reactive neutralizing antibodies in HIV-1 infected individuals |
| Q55373995 | Gp120 V5 Is Targeted by the First Wave of Sequential Neutralizing Antibodies in SHIVSF162P3N-Infected Rhesus Macaques. |
| Q30406365 | H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans |
| Q57071746 | HIV Superinfection Drives De Novo Antibody Responses and Not Neutralization Breadth |
| Q28487168 | HIV-1 Env C2-V4 Diversification in a Slow-Progressor Infant Reveals a Flat but Rugged Fitness Landscape |
| Q37360774 | HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity. |
| Q37073506 | HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds |
| Q42270590 | HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages |
| Q34657046 | HIV-1 neutralizing antibody response and viral genetic diversity characterized with next generation sequencing |
| Q37484124 | HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study |
| Q47254280 | HIV-1 superinfection can occur in the presence of broadly neutralizing antibodies |
| Q21090490 | HIV-1 superinfection in women broadens and strengthens the neutralizing antibody response |
| Q34527469 | HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. |
| Q40159913 | HIV-Specific B Cell Frequency Correlates with Neutralization Breadth in Patients Naturally Controlling HIV-Infection |
| Q27000480 | HIV‐1 neutralizing antibodies: understanding nature's pathways |
| Q35836169 | Honing a harder-hitting hammerhead improves broadly neutralizing antibody breadth and potency |
| Q35653703 | How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development? |
| Q38618790 | How to assess the binding strength of antibodies elicited by vaccination against HIV and other viruses |
| Q36076117 | Human Antibodies that Recognize Novel Immunodominant Quaternary Epitopes on the HIV-1 Env Protein |
| Q39108735 | Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies |
| Q38154471 | Human T follicular helper (Tfh) cells and disease |
| Q28602877 | Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies |
| Q34407843 | Human immunodeficiency virus type-1 (HIV-1) continues to evolve in presence of broadly neutralizing antibodies more than ten years after infection |
| Q37995555 | Human poly- and cross-reactive anti-viral antibodies and their impact on protection and pathology |
| Q30234773 | Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem |
| Q33620546 | Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection |
| Q42257910 | IL-21-producer CD4+ T cell kinetics during primary simian immunodeficiency virus infection |
| Q35592911 | Identification of CD4-Binding Site Dependent Plasma Neutralizing Antibodies in an HIV-1 Infected Indian Individual |
| Q34488183 | Identification of a new epitope for HIV-neutralizing antibodies in the gp41 membrane proximal external region by an Env-tailored phage display library |
| Q59357079 | Immune Correlate-Guided HIV Vaccine Design |
| Q38220506 | Immune System Regulation in the Induction of Broadly Neutralizing HIV-1 Antibodies |
| Q34434913 | Immunogenetics of small ruminant lentiviral infections |
| Q30353709 | Immunogenicity of membrane-bound HIV-1 gp41 membrane-proximal external region (MPER) segments is dominated by residue accessibility and modulated by stereochemistry. |
| Q35667479 | Immunogens Modeling a Fusion-Intermediate Conformation of gp41 Elicit Antibodies to the Membrane Proximal External Region of the HIV Envelope Glycoprotein |
| Q39108760 | Immunologic characteristics of HIV-infected individuals who make broadly neutralizing antibodies. |
| Q45324321 | Immunological and virological characteristics of human immunodeficiency virus type 1 superinfection: implications in vaccine design |
| Q34164923 | Immunotypes of a quaternary site of HIV-1 vulnerability and their recognition by antibodies |
| Q92210244 | Impact of HIV-1 Diversity on Its Sensitivity to Neutralization |
| Q60300903 | Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth |
| Q39113783 | Increased frequencies of CD8+CD57+ T cells are associated with antibody neutralization breadth against HIV in viraemic controllers |
| Q24631510 | Increasing the potency and breadth of an HIV antibody by using structure-based rational design |
| Q41885613 | Independent evolution of Fc- and Fab-mediated HIV-1-specific antiviral antibody activity following acute infection |
| Q37252966 | Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization |
| Q34791232 | Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes |
| Q42182937 | Insight into the modified Ibalizumab-human CD4 receptor interactions: using a computational binding free energy approach |
| Q50116524 | Integrity of Glycosylation Processing of a Glycan-Depleted Trimeric HIV-1 Immunogen Targeting Key B-Cell Lineages |
| Q36888400 | Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor |
| Q36831651 | Long antibody HCDR3s from HIV-naïve donors presented on a PG9 neutralizing antibody background mediate HIV neutralization |
| Q35826458 | Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity |
| Q37548026 | Loss of circulating CD4 T cells with B cell helper function during chronic HIV infection |
| Q64968778 | Lower Broadly Neutralizing Antibody Responses in Female Versus Male HIV-1 Infected Injecting Drug Users. |
| Q38945522 | Machine learning methods enable predictive modeling of antibody feature:function relationships in RV144 vaccinees |
| Q36239578 | Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting |
| Q38565206 | Mapping the Journey to an HIV Vaccine |
| Q36444787 | Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection |
| Q90323195 | Minding the gap: The impact of B-cell tolerance on the microbial antibody repertoire |
| Q36112751 | Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design. |
| Q37607358 | Modulation of nonneutralizing HIV-1 gp41 responses by an MHC-restricted TH epitope overlapping those of membrane proximal external region broadly neutralizing antibodies |
| Q36438523 | Most rhesus macaques infected with the CCR5-tropic SHIV AD8 generate cross-reactive antibodies that neutralize multiple HIV-1 strains |
| Q36568026 | Mouse marginal zone B cells harbor specificities similar to human broadly neutralizing HIV antibodies |
| Q47575476 | Moving ahead an HIV vaccine: To neutralize or not, a key HIV vaccine question |
| Q36121878 | Mycobacterium tuberculosis infection interferes with HIV vaccination in mice |
| Q40496744 | Natural evolution of broadly neutralizing antibodies |
| Q91582856 | Neutralization and beyond: Antibodies and HIV-1 acquisition |
| Q28483205 | Neutralization of tier-2 viruses and epitope profiling of plasma antibodies from human immunodeficiency virus type 1 infected donors from India |
| Q40120996 | Neutralizing Antibodies Against a Specific Human Immunodeficiency Virus gp41 Epitope are Associated With Long-term Non-progressor Status |
| Q37971867 | Neutralizing antibodies and control of HIV: moves and countermoves. |
| Q27684529 | Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor |
| Q36246315 | Neutralizing antibody escape during HIV-1 mother-to-child transmission involves conformational masking of distal epitopes in envelope |
| Q38058120 | Non-neutralizing antibodies in prevention of HIV infection |
| Q37668399 | Novel HIV vaccine strategies: overview and perspective |
| Q89407998 | Novel vaccines: Technology and development |
| Q39305961 | Pathogenic infection of Rhesus macaques by an evolving SIV-HIV derived from CCR5-using envelope genes of acute HIV-1 infections |
| Q28068018 | Patterns of HIV/SIV Prevention and Control by Passive Antibody Immunization |
| Q41699538 | Plasma CXCL13 but Not B Cell Frequencies in Acute HIV Infection Predicts Emergence of Cross-Neutralizing Antibodies |
| Q64984736 | Poly- and autoreactivity of HIV-1 bNAbs: implications for vaccine design. |
| Q24635002 | Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals |
| Q34992787 | Polyreactivity and autoreactivity among HIV-1 antibodies |
| Q35665921 | Potent intratype neutralizing activity distinguishes human immunodeficiency virus type 2 (HIV-2) from HIV-1 |
| Q40216624 | Preservation of Peripheral T Follicular Helper Cell Function in HIV Controllers |
| Q39315316 | Profiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B′-infected former plasma donors from China naïve to antiretroviral therapy |
| Q37621530 | Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies |
| Q40681333 | Quality and quantity of TFH cells are critical for broad antibody development in SHIVAD8 infection |
| Q34539819 | Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs |
| Q36155365 | Refined identification of neutralization-resistant HIV-1 CRF02_AG viruses |
| Q64057733 | Reverse Immunology Approach to Define a New HIV-gp41-Neutralizing Epitope |
| Q38213061 | Role of Fc-mediated antibody function in protective immunity against HIV-1. |
| Q35116581 | Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies |
| Q27670829 | Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding |
| Q54207383 | Sequential immunizations with a panel of HIV-1 Env virus-like particles coach immune system to make broadly neutralizing antibodies |
| Q37510603 | Soluble HIV-1 envelope immunogens derived from an elite neutralizer elicit cross-reactive V1V2 antibodies and low potency neutralizing antibodies |
| Q27677117 | Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization |
| Q92803580 | Star nanoparticles delivering HIV-1 peptide minimal immunogens elicit near-native envelope antibody responses in nonhuman primates |
| Q36132925 | Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120 |
| Q26829461 | Structural insights on the role of antibodies in HIV-1 vaccine and therapy |
| Q35985519 | Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability |
| Q35826171 | Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses |
| Q54210140 | Targeting the Latent Reservoir for HIV-1. |
| Q64060305 | The Antibodiome-Mapping the Humoral Immune Response to HIV |
| Q35686970 | The Broad Neutralizing Antibody Responses after HIV-1 Superinfection Are Not Dominated by Antibodies Directed to Epitopes Common in Single Infection |
| Q92561961 | The breadth of HIV-1 neutralizing antibodies depends on the conservation of key sites in their epitopes |
| Q36155396 | The development of CD4 binding site antibodies during HIV-1 infection |
| Q34252448 | The dysfunction of T follicular helper cells |
| Q52430553 | The latest evidence for possible HIV-1 curative strategies |
| Q35076717 | The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection |
| Q57170667 | The role of follicular helper CD4 T cells in the development of HIV-1 specific broadly neutralizing antibody responses |
| Q37547702 | The selection of low envelope glycoprotein reactivity to soluble CD4 and cold during simian-human immunodeficiency virus infection of rhesus macaques. |
| Q34048099 | Toll-like Receptor 7 Controls the Anti-Retroviral Germinal Center Response |
| Q36515149 | Towards HIV-1 remission: potential roles for broadly neutralizing antibodies |
| Q40932044 | Towards a vaccine against HIV: antibodies raised by a gp41 peptide neutralize the virus and inhibit pathogenesis |
| Q33854841 | Transplanting supersites of HIV-1 vulnerability |
| Q59350253 | Understanding the Determinants of BnAb Induction in Acute HCV Infection |
| Q35664155 | Vectored antibody gene delivery for the prevention or treatment of HIV infection |
| Q27676728 | Viral Escape from Neutralizing Antibodies in Early Subtype A HIV-1 Infection Drives an Increase in Autologous Neutralization Breadth |
| Q40346802 | Virus-driven Inflammation Is Associated With the Development of bNAbs in Spontaneous Controllers of HIV. |
| Q35641144 | What Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure? |
| Q35192660 | epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals |
Search more.